The development of Xarelto® (rivaroxaban), a novel oral anticoagulant, has taken another step forward. Phase II results in patients with acute coronary syndrome (ACS) have been chosen for the Late Br
read more » Discuss Add this link to...Bury Add to:
| Bookmarks